Inventiva S.A. (6IVA)
XBER 
Summary
Inventiva S.A. (IVA) Analyst/Investor Day Transcript
Inventiva S.A. (NASDAQ:IVA ) Analyst/Investor Day October 8, 2025 11:30 AM EDT Company Participants Mark Pruzanski Andrew Obenshain - CEO & Director Jason Campagna - President of Research and Development & Chief Medical Officer Martine Zimmermann - Executive VP of Regulatory Affairs & Quality Assurance Conference Call Participants William Alazawi Arun Sanyal Nezam H.
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Inventiva (IVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by.
Inventiva S.A. (6IVA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inventiva S.A. ever had a stock split?
Inventiva S.A. Profile
| Biotechnology Industry | Healthcare Sector | Andrew Obenshain CEO | XBER Exchange | US46124U1079 ISIN |
| FR Country | 114 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Inventiva S.A. is a trailblazer in the biopharmaceutical field, primarily engaged in discovering and developing oral small molecule therapies. Established in 2011, and operating from its headquarters in Daix, France, the company has positioned itself at the forefront of tackling complex diseases, with an emphasis on non-alcoholic steatohepatitis (NASH) and a variety of other significant diseases. Venturing beyond the traditional boundaries of medicine, Inventiva is committed to innovating solutions that have the potential to reshape treatments and improve patient outcomes significantly.
Products and Services
- Lanifibranor
Inventiva's flagship product, Lanifibranor, is an oral small molecule therapy currently undergoing a Phase III clinical trial aimed at treating non-alcoholic steatohepatitis (NASH), a liver disease with limited current treatment options. This therapeutic candidate stands out for its ability to address a critical unmet need in the healthcare sector, offering hope to patients suffering from this progressively worsening condition.
- Odiparcil
Another innovative product in Inventiva’s portfolio is Odiparcil, a therapy that has completed Phase IIa clinical trials and is designed to treat mucopolysaccharidoses type VI disease. This rare and serious condition affects the body's ability to break down large molecules, leading to severe symptoms that impact the quality of life. Odiparcil represents Inventiva’s commitment to addressing rare diseases with high unmet medical needs, showcasing the company's dedication to extending its research and development capabilities beyond its primary focus areas.
Beyond these leading product candidates, Inventiva continues to expand its horizon with a pipeline that encompasses earlier-stage programs targeting oncology and several other diseases. This approach exemplifies the company's strategic vision towards diversification and innovation, aiming to leverage its expertise in drug development to contribute significantly across a broad spectrum of healthcare challenges.
Contact Information
